{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T21:11:08Z","timestamp":1768770668101,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T00:00:00Z","timestamp":1444953600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"All the studies used in this analysis were funded by GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s13318-015-0303-4","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:03:17Z","timestamp":1445212997000},"page":"743-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease"],"prefix":"10.1007","volume":"41","author":[{"given":"Sarah","family":"Siederer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,16]]},"reference":[{"key":"303_CR1","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","volume":"23","author":"AJ Claxton","year":"2001","unstructured":"Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medical compliance. Clin Ther. 2001;23:1296\u2013310.","journal-title":"Clin Ther"},{"key":"303_CR2","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.clinthera.2012.06.005","volume":"34","author":"JA Boscia","year":"2012","unstructured":"Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C. Effect of once daily fluticasone furoate\/vilanterol on 24\u00a0h pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, cross-over study. Clin Ther. 2012;34:1656\u201366. doi: 10.1016\/j.clinthera.2012.06.005 .","journal-title":"Clin Ther"},{"key":"303_CR3","doi-asserted-by":"publisher","first-page":"e000370","DOI":"10.1136\/bmjopen-2011-000370","volume":"2","author":"J L\u00f6tvall","year":"2012","unstructured":"L\u00f6tvall J, Bakke PS, Bjermer L, Steinshamn S, Scott-Wilson C, Crim C, Sanford L, Haumann B. Efficacy and safety of 4\u00a0weeks\u2019 treatment with combined fluticasone furoate\/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open. 2012;2:e000370. doi: 10.1136\/bmjopen-2011-000370 .","journal-title":"BMJ Open."},{"key":"303_CR4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2125.1997.d01-1425.x","volume":"43","author":"L Thorsson","year":"1997","unstructured":"Thorsson L, Dahlstrom K, Edsbacker S, Kallen A, Paulson J, Wiren J-E. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1997;43:155\u201361.","journal-title":"Br J Clin Pharmacol"},{"key":"303_CR5","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1081-1206(10)60683-7","volume":"98","author":"DI Bernstein","year":"2007","unstructured":"Bernstein DI, Allen DB. Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol. 2007;98:118\u201327.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"303_CR6","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1378\/chest.125.6.2309","volume":"125","author":"SR Salpeter","year":"2004","unstructured":"Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004;125:2309\u201321.","journal-title":"Chest"},{"key":"303_CR7","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s40265-014-0269-6","volume":"74","author":"K McKeage","year":"2014","unstructured":"McKeage K. Fluticasone furoate\/vilanterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74:1509\u201322. doi: 10.1007\/s40265-014-0269-6 .","journal-title":"Drugs."},{"issue":"Suppl. 55","key":"303_CR8","first-page":"138s","volume":"38","author":"R Kempsford","year":"2011","unstructured":"Kempsford R, Allen A, Bareille P, Bishop H, Hamilton M, Cheesbrough A. The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination. Eur Respir J. 2011;38(Suppl. 55):138s.","journal-title":"Eur Respir J"},{"key":"303_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","volume":"35","author":"JE Ahn","year":"2008","unstructured":"Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM vilanterol. J Pharmacokinet Pharmacodyn. 2008;35:401\u201321. doi: 10.1007\/s10928-008-9094-4 .","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"303_CR10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.rmed.2012.12.014","volume":"107","author":"EM Kerwin","year":"2013","unstructured":"Kerwin EM, Scott-Wilson C, Sanford L, Rennard SI, Agusti A, Barnes N, Crim C. A randomised trial of fluticasone furoate\/vilanterol (50\/25\u00a0\u00b5g; 100\/25\u00a0\u00b5g) on lung function in COPD. Respir Med. 2013;107(4):560\u20139.","journal-title":"Respir Med"},{"issue":"4","key":"303_CR11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.rmed.2012.12.016","volume":"107","author":"FJ Martinez","year":"2013","unstructured":"Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PMA. Fluticasone furoate\/vilanterol (100\/25; 200\/25\u00a0\u00b5g) improves lung function in COPD: a randomised trial. Respir Med. 2013;107(4):550\u20139.","journal-title":"Respir Med"},{"key":"303_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bcp.12243","volume":"77","author":"R Kempsford","year":"2013","unstructured":"Kempsford R, Allen A, Kelly K, Saggu P, Crim C. A repeat-dose thorough QT study of inhaled fluticasone furoate (FF)\/vilanterol (VI) combination in healthy subjects. Br J Clin Pharmacol. 2013;77:466\u201379. doi: 10.1111\/bcp.12243 .","journal-title":"Br J Clin Pharmacol"},{"key":"303_CR13","unstructured":"R Development Core Team. R: a language and environment for statistical computing. 2008. R Foundation for Statistical Computing, Vienna, Austria. http:\/\/www.R-project.org . Accessed 4 Dec 2013."},{"key":"303_CR14","unstructured":"Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user\u2019s guides. 2009. Icon Development Solutions, Ellicott City, MD."},{"key":"303_CR15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO. Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51\u201364.","journal-title":"Comput Methods Programs Biomed"},{"key":"303_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35:185\u2013202. doi: 10.1007\/s10928-007-9081-1 .","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"303_CR17","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/bcp.12263","volume":"77","author":"A Allen","year":"2014","unstructured":"Allen A, Bal J, Cheesbrough A, Hamilton M, Kempsford R. Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Br J Clin Pharmacol. 2014;77:808\u201320. doi: 10.1111\/bcp.12263 .","journal-title":"Br J Clin Pharmacol"},{"key":"303_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s40262-013-0078-1","volume":"52","author":"A Allen","year":"2013","unstructured":"Allen A. The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmakinetics. 2013;52:885\u20139. doi: 10.1007\/s40262-013-0078-1 .","journal-title":"Clin Pharmakinetics."},{"key":"303_CR19","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.clinthera.2012.11.001","volume":"34","author":"A Allen","year":"2012","unstructured":"Allen A, Davis A, Hardes K, Tombs L, Kempsford R. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. Clin Ther. 2012;34:2316\u201332. doi: 10.1016\/j.clinthera.2012.11.001 .","journal-title":"Clin Ther"},{"key":"303_CR20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-015-0303-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-015-0303-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-015-0303-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-015-0303-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:06:10Z","timestamp":1553627170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-015-0303-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,16]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["303"],"URL":"https:\/\/doi.org\/10.1007\/s13318-015-0303-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,16]]}}}